866-997-4948(US-Canada Toll Free)

Ovarian Cancer - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Oct 2013

Category :

Ovarian Cancer

No. of Pages : 321 Pages

 

Global Markets Directs, \'Ovarian Cancer Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. Ovarian Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

 

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

Scope

 

  • A snapshot of the global therapeutic scenario for Ovarian Cancer.
  • A review of the Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Ovarian Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

 

Reasons to buy

 

  • Identify and understand important and diverse types of therapeutics under development for Ovarian Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Ovarian Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents


Table of Contents 2
List of Tables 7
List of Figures 12
Introduction 13
Global Markets Direct Report Coverage 13
Ovarian Cancer Overview 14
Therapeutics Development 15
An Overview of Pipeline Products for Ovarian Cancer 15
Ovarian Cancer Therapeutics under Development by Companies 17
Ovarian Cancer Therapeutics under Investigation by Universities/Institutes 30
Late Stage Products 33
Comparative Analysis 33
Mid Clinical Stage Products 34
Comparative Analysis 34
Early Clinical Stage Products 35
Comparative Analysis 35
Discovery and Pre-Clinical Stage Products 36
Comparative Analysis 36
Ovarian Cancer Therapeutics - Products under Development by Companies 37
Ovarian Cancer Therapeutics - Products under Investigation by Universities/Institutes 55
Companies Involved in Ovarian Cancer Therapeutics Development 58
Bristol-Myers Squibb Company 58
Johnson & Johnson 59
Boehringer Ingelheim GmbH 60
F. Hoffmann-La Roche Ltd. 61
Kyowa Hakko Kirin Co., Ltd. 62
Amgen Inc. 63
Sanofi-Aventis 64
AstraZeneca PLC 65
Eli Lilly and Company 66
Viralytics Ltd. 67
GlaxoSmithKline plc 68
Bioniche Life Sciences, Inc. 69
Tekmira Pharmaceuticals Corp. 70
Genentech, Inc. 71
Nektar Therapeutics 72
Bavarian Nordic A/S 73
Daiichi Sankyo Company, Ltd 74
Merck & Co., Inc. 75
AbGenomics International, Inc. 76
FASgen, Inc. 77
Dainippon Sumitomo Pharma Co., Ltd. 78
Oxford BioMedica plc 79
Generex Biotechnology Corporation 80
Amorfix Life Sciences Ltd. 81
Prolexys Pharmaceuticals, Inc. 82
Aposense Ltd. 83
Millennium Pharmaceuticals, Inc. 84
Novartis AG 85
Samyang Corporation 86
Aphios Corporation 87
Astellas Pharma Inc. 88
Chong Kun Dang Pharmaceutical 89
Eisai Co., Ltd. 90
ImmunoGen, Inc. 91
Pfizer Inc. 92
Sigma-Tau S.p.A. 93
Sunesis Pharmaceuticals, Inc. 94
SuperGen, Inc. 95
Taiho Pharmaceutical Co., Ltd. 96
Cell Therapeutics, Inc. 97
Santaris Pharma A/S 98
Exelixis, Inc. 99
Aduro BioTech 100
Menarini Group 101
Alfacell Corporation 102
Celgene Corporation 103
Onyx Pharmaceuticals, Inc. 104
Bayer AG 105
AntiCancer, Inc. 106
Merck KGaA 107
Access Pharmaceuticals, Inc. 108
Advaxis, Inc. 109
Neogenix Oncology Corporation 110
EntreMed, Inc. 111
Hana Biosciences, Inc. 112
Celldex Therapeutics, Inc. 113
ValiRx Plc 114
AEterna Zentaris Inc. 115
ImmunoCellular Therapeutics, Ltd. 116
IMMUNOMEDICS, INC 117
Lorus Therapeutics Inc 118
Marshall Edwards, Inc. 119
Basilea Pharmaceutica Ltd. 120
Bionomics Limited 121
Northwest Biotherapeutics, Inc. 122
Novogen Limited 123
Cleveland BioLabs, Inc. 124
Oncolytics Biotech Inc. 125
OXiGENE, Inc. 126
Critical Outcome Technologies Inc. 127
Alnylam Pharmaceuticals, Inc 128
Cytokinetics, Inc 129
Telik, Inc. 130
VioQuest Pharmaceuticals, Inc. 131
Oncogenex Pharmaceuticals, Inc. 132
Dendreon Corporation 133
Prima BioMed Limited 134
Progen Pharmaceuticals Limited 135
Innocell Corporation 136
PharmaGap Inc. 137
Quest PharmaTech Inc. 138
Synta Pharmaceuticals Corp. 139
ThromboGenics NV 140
Oasmia Pharmaceutical AB 141
Rexahn Pharmaceuticals, Inc. 142
Morphotek, Inc. 143
Cancer Research Technology Limited 144
Spectrum Pharmaceuticals, Inc. 145
Chipscreen Biosciences Ltd 146
Supratek Pharma Inc. 147
GANYMED Pharmaceuticals AG 148
Acceleron Pharma, Inc. 149
Nerviano Medical Sciences S.r.l. 150
Glycotope GmbH 151
TRION Pharma GmbH 152
Advantagene, Inc. 153
BioNumerik Pharmaceuticals, Inc. 154
Alethia Biotherapeutics Inc. 155
OnKor Pharmaceuticals, Inc. 156
Coronado Biosciences, Inc. 157
Cerulean Pharma, Inc. 158
Heat Biologics, Inc. 159
MacroGenics, Inc. 160
Fresenius Biotech GmbH 161
Pantarhei Bioscience BV 162
Azaya Therapeutics, Inc. 163
CanBas Co., Ltd. 164
Merrimack Pharmaceuticals, Inc. 165
Spirogen Ltd. 166
Neotropix, Inc. 167
Innate Therapeutics Limited 168
Conatus Pharmaceuticals Inc. 169
CritiTech, Inc. 170
Deciphera Pharmaceuticals, LLC 171
Vascular Biogenics Ltd. 172
BioCancell Therapeutics, Inc. 173
Advenchen Laboratories, LLC 174
Onconova Therapeutics, Inc 175
MolMed S.p.A. 176
Viral Genetics, Inc. 177
Immunotope, Inc. 178
Esperance Pharmaceuticals, Inc. 179
Omeros Corporation 180
Bolder Biotechnology, Inc. 181
ImmunoVaccine Technologies Inc. 182
Welichem Biotech Inc. 183
Angstrom Pharmaceuticals, Inc. 184
NewLink Genetics Corporation 185
PharmaMar, S.A. 186
TVAX Biomedical, LLC 187
Quintessence Biosciences, Inc. 188
AmpliMed Corporation 189
Tigris Pharmaceuticals, Inc. 190
Viventia Biotechnologies Inc. 191
TRACON Pharmaceuticals, Inc. 192
Medestea Research & Production S.p.A. 193
Domainex Ltd. 194
Anaphore, Inc. 195
Clovis Oncology, Inc. 196
Oncolix, Inc. 197
OHR Pharmaceutical Inc. 198
Cancer Therapeutics CRC Pty Ltd 199
BioProspecting NB, Inc. 200
RECEPTA Biopharma S.A. 201
Bioo Therapeutics 202
Jiangsu Kanion Pharmaceutical Co., Ltd. 203
NovaBioMed Inc 204
PepTx, Inc. 205
Mebiopharm Co., Ltd. 206
DEKK-TEC, Inc. 207
ISA Pharmaceuticals B.V. 208
TAU Therapeutics, LLC 209
Gradalis Inc. 210
Ovarian Cancer - Therapeutics Assessment 211
Assessment by Monotherapy Products 211
Assessment by Combination Products 212
Assessment by Route of Administration 213
Assessment by Molecule Type 216
Drug Profiles 219
trebananib - Drug Profile 219
paclitaxel poliglumex - Drug Profile 222
farletuzumab - Drug Profile 226
paclitaxel - Drug Profile 229
canfosfamide hydrochloride - Drug Profile 231
idronoxil - Drug Profile 235
nintedanib - Drug Profile 237
CVac - Drug Profile 239
tirapazamine - Drug Profile 242
vintafolide - Drug Profile 243
vintafolide - Drug Profile 246
idronoxil + [carboplatin] - Drug Profile 249
trebananib + [doxorubicin liposomal] - Drug Profile 251
trabectedin + [doxorubicin liposomal] - Drug Profile 253
cositecan - Drug Profile 254
bevacizumab - Drug Profile 256
bevacizumab - Drug Profile 260
pazopanib hydrochloride - Drug Profile 264
trabectedin - Drug Profile 267
trebananib + [carboplatin] + [paclitaxel] - Drug Profile 270
Ovarian Cancer Therapeutics - Drug Profile Updates 272
Ovarian Cancer Therapeutics - Discontinued Products 294
Ovarian Cancer Therapeutics - Dormant Products 296
Ovarian Cancer - Product Development Milestones 310
Featured News & Press Releases 310


Appendix 318
Methodology 318
Coverage 318
Secondary Research 318
Primary Research 318
Expert Panel Validation 318
Contact Us 319
Disclaimer 319

List of Table


Number of Products Under Development for Ovarian Cancer, H2 2013 17
Products under Development for Ovarian Cancer - Comparative Analysis, H2 2013 18
Number of Products under Development by Companies, H2 2013 20
Number of Products under Development by Companies, H2 2013 (Contd..1) 21
Number of Products under Development by Companies, H2 2013 (Contd..2) 22
Number of Products under Development by Companies, H2 2013 (Contd..3) 23
Number of Products under Development by Companies, H2 2013 (Contd..4) 24
Number of Products under Development by Companies, H2 2013 (Contd..5) 25
Number of Products under Development by Companies, H2 2013 (Contd..6) 26
Number of Products under Development by Companies, H2 2013 (Contd..7) 27
Number of Products under Development by Companies, H2 2013 (Contd..8) 28
Number of Products under Development by Companies, H2 2013 (Contd..9) 29
Number of Products under Development by Companies, H2 2013 (Contd..10) 30
Number of Products under Development by Companies, H2 2013 (Contd..11) 31
Number of Products under Investigation by Universities/Institutes, H2 2013 33
Number of Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 34
Comparative Analysis by Late Stage Development, H2 2013 35
Comparative Analysis by Mid Clinical Stage Development, H2 2013 36
Comparative Analysis by Early Clinical Stage Development, H2 2013 37
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 38
Products under Development by Companies, H2 2013 39
Products under Development by Companies, H2 2013 (Contd..1) 40
Products under Development by Companies, H2 2013 (Contd..2) 41
Products under Development by Companies, H2 2013 (Contd..3) 42
Products under Development by Companies, H2 2013 (Contd..4) 43
Products under Development by Companies, H2 2013 (Contd..5) 44
Products under Development by Companies, H2 2013 (Contd..6) 45
Products under Development by Companies, H2 2013 (Contd..7) 46
Products under Development by Companies, H2 2013 (Contd..8) 47
Products under Development by Companies, H2 2013 (Contd..9) 48
Products under Development by Companies, H2 2013 (Contd..10) 49
Products under Development by Companies, H2 2013 (Contd..11) 50
Products under Development by Companies, H2 2013 (Contd..12) 51
Products under Development by Companies, H2 2013 (Contd..13) 52
Products under Development by Companies, H2 2013 (Contd..14) 53
Products under Development by Companies, H2 2013 (Contd..15) 54
Products under Development by Companies, H2 2013 (Contd..16) 55
Products under Development by Companies, H2 2013 (Contd..17) 56
Products under Investigation by Universities/Institutes, H2 2013 57
Products under Investigation by Universities/Institutes, H2 2013 (Contd..1) 58
Products under Investigation by Universities/Institutes, H2 2013 (Contd..2) 59
Bristol-Myers Squibb Company, H2 2013 60
Johnson & Johnson, H2 2013 61
Boehringer Ingelheim GmbH, H2 2013 62
F. Hoffmann-La Roche Ltd., H2 2013 63
Kyowa Hakko Kirin Co., Ltd., H2 2013 64
Amgen Inc., H2 2013 65
Sanofi-Aventis, H2 2013 66
AstraZeneca PLC, H2 2013 67
Eli Lilly and Company, H2 2013 68
Viralytics Ltd., H2 2013 69
GlaxoSmithKline plc, H2 2013 70
Bioniche Life Sciences, Inc., H2 2013 71
Tekmira Pharmaceuticals Corp., H2 2013 72
Genentech, Inc., H2 2013 73
Nektar Therapeutics, H2 2013 74
Bavarian Nordic A/S, H2 2013 75
Daiichi Sankyo Company, Ltd, H2 2013 76
Merck & Co., Inc., H2 2013 77
AbGenomics International, Inc., H2 2013 78
FASgen, Inc., H2 2013 79
Dainippon Sumitomo Pharma Co., Ltd., H2 2013 80
Oxford BioMedica plc, H2 2013 81
Generex Biotechnology Corporation, H2 2013 82
Amorfix Life Sciences Ltd., H2 2013 83
Prolexys Pharmaceuticals, Inc., H2 2013 84
Aposense Ltd., H2 2013 85
Millennium Pharmaceuticals, Inc., H2 2013 86
Novartis AG, H2 2013 87
Samyang Corporation, H2 2013 88
Aphios Corporation, H2 2013 89
Astellas Pharma Inc., H2 2013 90
Chong Kun Dang Pharmaceutical, H2 2013 91
Eisai Co., Ltd., H2 2013 92
ImmunoGen, Inc., H2 2013 93
Pfizer Inc., H2 2013 94
Sigma-Tau S.p.A., H2 2013 95
Sunesis Pharmaceuticals, Inc., H2 2013 96
SuperGen, Inc., H2 2013 97
Taiho Pharmaceutical Co., Ltd., H2 2013 98
Cell Therapeutics, Inc., H2 2013 99
Santaris Pharma A/S, H2 2013 100
Exelixis, Inc., H2 2013 101
Aduro BioTech, H2 2013 102
Menarini Group, H2 2013 103
Alfacell Corporation, H2 2013 104
Celgene Corporation, H2 2013 105
Onyx Pharmaceuticals, Inc., H2 2013 106
Bayer AG, H2 2013 107
AntiCancer, Inc., H2 2013 108
Merck KGaA, H2 2013 109
Access Pharmaceuticals, Inc., H2 2013 110
Advaxis, Inc., H2 2013 111
Neogenix Oncology Corporation, H2 2013 112
EntreMed, Inc., H2 2013 113
Hana Biosciences, Inc., H2 2013 114
Celldex Therapeutics, Inc., H2 2013 115
ValiRx Plc, H2 2013 116
AEterna Zentaris Inc., H2 2013 117
ImmunoCellular Therapeutics, Ltd., H2 2013 118
IMMUNOMEDICS, INC, H2 2013 119
Lorus Therapeutics Inc, H2 2013 120
Marshall Edwards, Inc., H2 2013 121
Basilea Pharmaceutica Ltd., H2 2013 122
Bionomics Limited, H2 2013 123
Northwest Biotherapeutics, Inc., H2 2013 124
Novogen Limited, H2 2013 125
Cleveland BioLabs, Inc., H2 2013 126
Oncolytics Biotech Inc., H2 2013 127
OXiGENE, Inc., H2 2013 128
Critical Outcome Technologies Inc., H2 2013 129
Alnylam Pharmaceuticals, Inc, H2 2013 130
Cytokinetics, Inc, H2 2013 131
Telik, Inc., H2 2013 132
VioQuest Pharmaceuticals, Inc., H2 2013 133
Oncogenex Pharmaceuticals, Inc., H2 2013 134
Dendreon Corporation, H2 2013 135
Prima BioMed Limited, H2 2013 136
Progen Pharmaceuticals Limited, H2 2013 137
Innocell Corporation, H2 2013 138
PharmaGap Inc., H2 2013 139
Quest PharmaTech Inc., H2 2013 140
Synta Pharmaceuticals Corp., H2 2013 141
ThromboGenics NV, H2 2013 142
Oasmia Pharmaceutical AB, H2 2013 143
Rexahn Pharmaceuticals, Inc., H2 2013 144
Morphotek, Inc., H2 2013 145
Cancer Research Technology Limited, H2 2013 146
Spectrum Pharmaceuticals, Inc., H2 2013 147
Chipscreen Biosciences Ltd, H2 2013 148
Supratek Pharma Inc., H2 2013 149
GANYMED Pharmaceuticals AG, H2 2013 150
Acceleron Pharma, Inc., H2 2013 151
Nerviano Medical Sciences S.r.l., H2 2013 152
Glycotope GmbH, H2 2013 153
TRION Pharma GmbH, H2 2013 154
Advantagene, Inc.H2 2013 155
BioNumerik Pharmaceuticals, Inc., H2 2013 156
Alethia Biotherapeutics Inc., H2 2013 157
OnKor Pharmaceuticals, Inc., H2 2013 158
Coronado Biosciences, Inc., H2 2013 159
Cerulean Pharma, Inc., H2 2013 160
Heat Biologics, Inc., H2 2013 161
MacroGenics, Inc., H2 2013 162
Fresenius Biotech GmbH, H2 2013 163
Pantarhei Bioscience BV, H2 2013 164
Azaya Therapeutics, Inc., H2 2013 165
CanBas Co., Ltd., H2 2013 166
Merrimack Pharmaceuticals, Inc., H2 2013 167
Spirogen Ltd., H2 2013 168
Neotropix, Inc., H2 2013 169
Innate Therapeutics Limited, H2 2013 170
Conatus Pharmaceuticals Inc., H2 2013 171
CritiTech, Inc., H2 2013 172
Deciphera Pharmaceuticals, LLC, H2 2013 173
Vascular Biogenics Ltd., H2 2013 174
BioCancell Therapeutics, Inc., H2 2013 175
Advenchen Laboratories, LLC, H2 2013 176
Onconova Therapeutics, Inc, H2 2013 177
MolMed S.p.A., H2 2013 178
Viral Genetics, Inc., H2 2013 179
Immunotope, Inc., H2 2013 180
Esperance Pharmaceuticals, Inc., H2 2013 181
Omeros Corporation, H2 2013 182
Bolder Biotechnology, Inc., H2 2013 183
ImmunoVaccine Technologies Inc., H2 2013 184
Welichem Biotech Inc., H2 2013 185
Angstrom Pharmaceuticals, Inc., H2 2013 186
NewLink Genetics Corporation ,H2 2013 187
PharmaMar, S.A., H2 2013 188
TVAX Biomedical, LLC, H2 2013 189
Quintessence Biosciences, Inc., H2 2013 190
AmpliMed Corporation, H2 2013 191
Tigris Pharmaceuticals, Inc., H2 2013 192
Viventia Biotechnologies Inc., H2 2013 193
TRACON Pharmaceuticals, Inc., H2 2013 194
Medestea Research & Production S.p.A., H2 2013 195
Domainex Ltd., H2 2013 196
Anaphore, Inc., H2 2013 197
Clovis Oncology, Inc., H2 2013 198
Oncolix, Inc., H2 2013 199
OHR Pharmaceutical Inc., H2 2013 200
Cancer Therapeutics CRC Pty Ltd, H2 2013 201
BioProspecting NB, Inc., H2 2013 202
RECEPTA Biopharma S.A., H2 2013 203
Bioo Therapeutics, H2 2013 204
Jiangsu Kanion Pharmaceutical Co., Ltd., H2 2013 205
NovaBioMed Inc, H2 2013 206
PepTx, Inc., H2 2013 207
Mebiopharm Co., Ltd., H2 2013 208
DEKK-TEC, Inc., H2 2013 209
ISA Pharmaceuticals B.V., H2 2013 210
TAU Therapeutics, LLC, H2 2013 211
Gradalis Inc., H2 2013 212
Assessment by Monotherapy Products, H2 2013 213
Assessment by Combination Products, H2 2013 214
Assessment by Stage and Route of Administration, H2 2013 217
Assessment by Stage and Molecule Type, H2 2013 220
Ovarian Cancer Therapeutics - Drug Profile Updates 274
Ovarian Cancer Therapeutics - Discontinued Products 296
Ovarian Cancer Therapeutics - Discontinued Products (Contd..1) 297
Ovarian Cancer Therapeutics - Dormant Products 298
Ovarian Cancer Therapeutics - Dormant Products (Contd..1) 299
Ovarian Cancer Therapeutics - Dormant Products (Contd..2) 300
Ovarian Cancer Therapeutics - Dormant Products (Contd..3) 301
Ovarian Cancer Therapeutics - Dormant Products (Contd..4) 302
Ovarian Cancer Therapeutics - Dormant Products (Contd..5) 303
Ovarian Cancer Therapeutics - Dormant Products (Contd..6) 304
Ovarian Cancer Therapeutics - Dormant Products (Contd..7) 305
Ovarian Cancer Therapeutics - Dormant Products (Contd..8) 306
Ovarian Cancer Therapeutics - Dormant Products (Contd..9) 307
Ovarian Cancer Therapeutics - Dormant Products (Contd..10) 308
Ovarian Cancer Therapeutics - Dormant Products (Contd..11) 309
Ovarian Cancer Therapeutics - Dormant Products (Contd..12) 310
Ovarian Cancer Therapeutics - Dormant Products (Contd..13) 311

List of Chart


Number of Products under Development for Ovarian Cancer, H2 2013 17
Products under Development for Ovarian Cancer - Comparative Analysis, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 32
Late Stage Products, H2 2013 35
Mid Clinical Stage Products, H2 2013 36
Early Clinical Stage Products, H2 2013 37
Discovery and Pre-Clinical Stage Products, H2 2013 38
Assessment by Monotherapy Products, H2 2013 213
Assessment by Combination Products, H2 2013 214
Assessment by Route of Administration, H2 2013 215
Assessment by Stage and Route of Administration, H2 2013 216
Assessment by Molecule Type, H2 2013 218
Assessment by Stage and Molecule Type, H2 2013 219

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *